Rhythm Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of therapeutics for rare genetic diseases related to obesity. Its flagship product IMCIVREE is a melanocortin-4 receptor used to treat POMC and other types of obesity. The company is also developing Setmelanotide, which is in Phase II trials and could help treat various genetic obesity conditions.